

MEDIVOX LIMITED

**Company Registration Number:
13296708 (England and Wales)**

Unaudited micro entity accounts for the year ended 31 March 2023

Period of accounts

Start date: 01 April 2022

End date: 31 March 2023

MEDIVOX LIMITED

Contents of the Financial Statements

for the Period Ended 31 March 2023

Company Information - 3

Report of the Directors - 4

Balance sheet - 5

Footnotes to the Balance Sheet - 7

MEDIVOX LIMITED

Company Information

for the Period Ended 31 March 2023

Director:

Mark William Lenherr

Simon James Blakebrough

Registered office:

18
Upper Mall
London
GBR
W6 9TA

Company Registration Number:

13296708 (England and Wales)

MEDIVOX LIMITED

Directors' Report Period Ended 31 March 2023

The directors present their report with the financial statements of the company for the period ended 31 March 2023

Principal Activities

Manufacture of other inorganic basic chemicals, Wholesale of chemical products and Research and experimental development on biotechnology.

Directors

The directors shown below have held office during the whole of the period from 01 April 2022 to 31 March 2023

Mark William Lenherr

Simon James Blakebrough

This report was approved by the board of directors on 28 November 2023

And Signed On Behalf Of The Board By:

Name: Mark William Lenherr

Status: Director

MEDIVOX LIMITED

Balance sheet

As at 31 March 2023

	<i>2023</i> <i>£</i>	<i>2022</i> <i>£</i>
Current assets:	15,521	20,120
Creditors: amounts falling due within one year:	(852,559)	(538,060)
Net current assets (liabilities):	(837,038)	(517,940)
Total assets less current liabilities:	(837,038)	(517,940)
Creditors: amounts falling due after more than one year:	(331,114)	(277,000)
Total net assets (liabilities):	(1,168,152)	(794,940)
Capital and reserves:	(1,168,152)	(794,940)

MEDIVOX LIMITED

Balance sheet continued

For the year ending 31 March 2023 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions of the small companies regime applicable to micro-entities.

This report was approved by the board of directors on 28 November 2023

And Signed On Behalf Of The Board By:

Name: Mark William Lenherr

Status: Director

The notes form part of these financial statements

MEDIVOX LIMITED

Footnotes to the Financial Statements

for the Period Ended 31 March 2023

1. Employee Information

Average number of employees: 0

MEDIVOX LIMITED

Footnotes to the Financial Statements

for the Period Ended 31 March 2023

2. Off balance sheet disclosure

No

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.